Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZN-c3 + ZN-d5 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZN-c3 | ZNc3|ZN c3|azenosertib | WEE1 Inhibitor 8 | ZN-c3 is a small molecular inhibitor of WEE1 and inhibition of WEE1 increases DNA damage in cancer cells to induce programmed cell death (J Clin Oncol 41, 2023 (suppl 16; abstr 5513)). | |
ZN-d5 | ZN d5|ZNd5 | BCL2 inhibitor 27 | ZN-d5 inhibits BCL-2, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (Annals of Oncology, 32, S594-S595). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05682170 | Phase Ib/II | ZN-c3 + ZN-d5 ZN-c3 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |